STRATA Skin Sciences Faces Going Concern Doubt After Nasdaq Delisting, Debt Default, and Massive Tax Liabilities

summarizeSummary

STRATA Skin Sciences issued a going concern warning after its Nasdaq delisting and debt default, while facing massive sales tax liabilities and the termination of its ATM equity program.

check_boxKey Events

• Going Concern Warning Issued

  Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses and dependence on external capital.

• Nasdaq Delisting and OTC Trading

  The company's common stock was delisted from The Nasdaq Capital Market on February 19, 2026, and now trades over-the-counter, severely limiting market liquidity.

• Debt Default and Acceleration Risk

  The Nasdaq delisting constitutes an event of default under the Senior Term Facility with MidCap, allowing the lender to accelerate the entire $15.0 million outstanding debt.

• Significant Sales Tax Liabilities

  The company paid $1.3 million to New York following an adverse court ruling on sales tax applicability, with an additional $0.6 million remaining for New York and $2.4 million in California assessments still under appeal.

auto_awesomeAnalysis

STRATA Skin Sciences is in severe financial distress, evidenced by a going concern warning, recent Nasdaq delisting, and an event of default on its long-term debt. The company's common stock was delisted on February 19, 2026, and now trades over-the-counter, significantly impacting liquidity and investor confidence. This delisting triggered an event of default under its Senior Term Facility with MidCap, allowing the lender to accelerate the entire $15.0 million debt. Furthermore, the company faces substantial sales and use tax liabilities, with $1.3 million already paid to New York following an adverse court ruling, and an additional $0.6 million remaining for New York, plus $2.4 million in California assessments still under appeal. These tax liabilities represent a massive burden relative to the company's market capitalization. The ATM equity distribution program, which provided $3.6 million in net proceeds in 2025, has been terminated due to the delisting, removing a critical source of future liquidity. The company also reported a material weakness in internal controls over financial reporting, indicating significant financial reporting risks. The combination of these factors presents an existential threat to the company's operations and financial viability.